Trending

Ozempic

FDA approves MACE label claim for Lilly’s Trulicity

FDA approves MACE label claim for Lilly’s Trulicity

Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for

X

FDA approves MACE label claim for Lilly’s Trulicity

https://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Solid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat

X

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

https://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but

X

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

https://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the

X

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

https://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/

Novo Nordisk hints at US price cuts after Q2 sales fall

Novo Nordisk hints at US price cuts after Q2 sales fall

Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of

X

Novo Nordisk hints at US price cuts after Q2 sales fall

https://pharmaphorum.com/news/novo-nordisk-price-reductions/

Trulicity helps SGLT-2 patients lower blood sugar

Trulicity helps SGLT-2 patients lower blood sugar

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

X

Trulicity helps SGLT-2 patients lower blood sugar

https://pharmaphorum.com/news/trulicity-sglt-2-drug-combo-doesnt-boost-blood-sugar-lowering/

Novo Nordisk undeterred after losing out on Ablynx takeover

Novo Nordisk undeterred after losing out on Ablynx takeover

After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.

X

Novo Nordisk undeterred after losing out on Ablynx takeover

https://pharmaphorum.com/news/novo-nordisk-undeterred-losing-ablynx-takeover/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com